The use of mycophenolate mofetil (MMF) for prophylaxis of aGVHD and/or for treatment of acute or chronic GVHD is increasing. However, the benefit of MMF as an alternative to commonly used immunosuppressive agents still needs to be assessed. We ran a retrospective study on 21 consecutive patients (median age, 36 years; range, 20-63) with aGVHD or extensive cGVHD following related (17) or unrelated (4) matched donor SCT (BM, 16; PBSC, 5) who received MMF (2 g/day) because of intolerance to or failure of CsA-containing combinations. Four of the six patients with aGVHD responded, and the response rate was 69% in cGVHD patients. We observed neither significant differences in terms of response rate for skin, liver and bowel nor dissociated response in cases of multiple organ involvement (67% of the patients). Response was the same for lichenoid and sclerodermatous skin cGVHD subtypes. No adverse effects, except diarrhea (three patients), were observed. However, 22 opportunistic or serious viral or bacterial infections occurred in 10 patients. Analysis of trough plasma levels showed a trend for a higher mean MPA concentration in patients responding to MMF. Our study highlights the high risk of infectious complications induced by the administration of MMF, an otherwise efficient and well-tolerated treatment for GVHD.
complete lymphohematopoietic chimerism, 1 approximately 50% of transplanted patients develop severe GVHD which is the main cause of morbidity and mortality after allogeneic stem cell transplantation. [2] [3] [4] [5] [6] [7] Improvement in prophylactic GVHD regimens or treatments remains one of the greatest challenges. 8, 9 The most frequently used prophylaxis for GVHD includes the combination of cyclosporine (CsA), corticosteroids, short-course methotrexate, and/or antithymocyte globulin. 10, 11 CsA and steroids are effective in the treatment of acute GVHD (aGVHD), as well as established chronic GVHD (cGVHD). However, therapeutic options are limited in cases of resistance to first-line therapy, and alternative treatments including thalidomide, tacrolimus, ultraviolet irradiation and psoralen (PUVA), total lymphoid irradiation, photopheresis, etretinate and clofazimine do not always control GVHD. [12] [13] [14] [15] Mycophenolic acid, the active metabolite of mycophenolate mofetil (MMF, CellCept), selectively suppresses proliferation of T and B lymphocytes, formation of antibodies, and glycosylation of adhesion molecules by inhibiting purine nucleotide synthesis and depleting lymphocytes and monocytes of guanosine triphosphate. 16 MMF is successfully used in the prevention of acute rejection of renal allografts, 17 demonstrating even more efficacy than azathioprine. 18 This immunosuppressive agent might also be useful in the treatment of auto-immune diseases, such as diffuse proliferative lupus nephritis, in combination with prednisolone. 19 Preliminary clinical studies suggest that MMF might be an effective agent for prophylaxis of aGVHD 1, 20, 21 and/or treatment of acute 22, 23 or chronic 14, 22 GVHD after allogeneic BMT or PBSCT in adult patients or in children, 24 when administered alone or in combination with other immunosuppressive agents (CsA Ϯ prednisolone, 21,22 tacrolimus 14 ). However, few data are available. In the largest series of patients reported by Basara et al, 22 MMF was administered in combination with CsA and prednisolone in 30 patients with acute (21 patients) or chronic (9 patients) GVHD; overall grade improvement of aGVHD was found in 71% of patients and MMF therapy led to moderate improvment in 50% of patients with limited cGVHD. Used as a salvage therapy for refractory GVHD, MMF induced 46% objective response in a series of 26 adult patients, 14 while an overall response rate of 60% (complete and partial response) has been reported in a series of 15 children. 24 The bioavailability of the oral formulation of MMF, especially in patients with GVHD of the bowel, might be an important factor influencing the efficacy of MMF and the use of an i.v. formulation of MMF in combination with CsA and prednisolone in the prophylaxis of aGVHD has been evaluated. 1 The aim of the present retrospective study was to evaluate the safety and efficacy of MMF as treatment for acute or chronic GVHD in a series of 21 allograft patients.
Patients and methods

Patients
We retrospectively studied 21 patients (13M/8F; median age, 36 years; range, 20-63) given a sibling bone marrow (BM) or peripheral blood (PB) stem cell (SC) transplant (12 and five patients, respectively) or an allogeneic matchedunrelated donor BMT (four patients), who received MMF for the treatment of acute (six patients) or chronic GVHD (15 patients). All transplants were HLA matched and had been performed between January 1995 and July 2000 at our institution. The underlying disease was acute myeloid leukemia (AML) in six patients, refractory anemia with excess of blasts (RAEB) in two patients, chronic myeloid leukemia (CML) in four patients, osteomyelofibrosis (OMF) in one patient, acute lymphoblastic leukemia (ALL) in two patients (one Ph1ϩ; one Ph1Ϫ), non-Hodgkin's lymphoma (NHL) in four patients, multiple myeloma (MM) in one patient, and chronic lymphoid leukemia (CLL) in one patient. Twelve patients were transplanted with early disease (six patients with acute leukemia in first complete remission (CR), five patients CML or OMF in first chronic phase, one patient with MM in very good partial response) and nine patients with advanced disease (one AML in CR2; one refractory ALL Ph1ϩ; two untreated RAEB; five chronic lymphoproliferative disorders in CR Ն2 or refractory to treatment including two patients who relapsed after autologous PBSC transplant). Patient characteristics are depicted in Table 1 .
Conditioning included total body irradiation (TBI, 2 ϫ 2 Gy/day from day Ϫ6 to day Ϫ4) and cyclophosphamide (Cy, 60 mg/kg/day from day Ϫ3 to day Ϫ2) in 17 patients, while three patients (two ALL, one T-NHL) received a combination of TBI/Cy and etoposide (VP16, 40 mg/kg 1 day) and one patient (aged 63 years) received a combination of fludarabine/antilymphocyte serum/busulfan as nonmyeloablative conditioning. Acute GVHD prophylaxis consisted of a combination of CsA as a continuous infusion of 3 mg/kg/day starting on day Ϫ1 and methotrexate (MTX) given on day ϩ1 (15 mg/m 2 ) and day ϩ3 and ϩ6 (10 mg/m 2 ). Further intravenous or oral CsA was adapted according to CsA trough blood levels (targeted blood level, 150 to 300 mg/l). During aplasia, from day 2 to day 30 post transplant, antiviral prophylaxis (aciclovir 500 mg/m 2 three times a day) was administered when recipient and/or donor were serologically positive for cytomegalovirus. After transplantation and hematopoietic recovery, all patients received prophylaxis against infections due to encapsulated organisms, such as pneumococcus (penicillin or roxithromycin) and Pneumocystis carinii pneumonia (TMP-SMX or pentamidine) and no further antiviral prophylaxis was administered. No additional antimicrobial prophylaxis was administered following the introduction of MMF.
GVHD treatment
Acute GVHD was graded and staged according to the Consensus Conference on aGVHD grading. 23 Eighteen patients developed aGVHD (grade I-II, three patients; grade II, 11 patients; grade III, three patients; grade IV, one patient) with skin involvement (18 cases), and/or liver (five cases) and/or bowel aGVHD (five cases) ( Table 1 ). First-line aGVHD treatment consisted of a combination of CsA and steroids in 17 patients. Alternative aGVHD treatments (antilymphocyte serum, anti-RIL2 antibody, MMF), were introduced alone or in combination in eight patients because of non-response (five cases) and/or intolerance to CsA/steroids (six cases). One patient received MMF as first-line treatment because of kidney failure precluding the reintroduction of CsA. Chronic GVHD was graded and staged according to the clinicopathological classification of GVHD. 25 Sixteen patients developed extensive cGVHD requiring continuation of immunosuppressive treatment, with skin (15 cases: nine lichenoid-, four sclerodermatous-, two mixed-profiles) and/or liver (11 cases) and/or bowel involvement (four cases). Mean delay between transplant and the onset of cGVHD was 184 days (range, 94-408 days). Multiple organ involvement was observed in 67% of the patients in this series.
In most cases the diagnosis of GVHD was proven by biopsy. Overall, the diagnosis of skin aGVHD or cGVHD was kept in all 21 patients in our series and biopsy proven in 18 patients; in the three remaining patients no skin biopsy was performed and the diagnosis was maintained based on clinical examination and/or the association of the cutaneous lesions with liver function test abnormalities or diarrhea (two patients). A diagnosis of GI GVHD was retained in only six patients presenting with significant diarrhea or weight loss. Results of histopathological analyses were compatible with GVHD in three out of the five patients for whom biopsies were performed. In five additional patients the diagnosis of GI GVHD was not retained because of lack of histopathological evidence for GVHD on GI biopsies and a small volume of diarrhea. Thirteen patients were considered as having liver GVHD: in two patients the diagnosis was confirmed on histopathology. In 10 patients, no liver biopsy was performed and the diagnosis of liver GVHD was retained because of the association with skin or GI involvement (biopsy proven in nine cases out of 10). In one patient with biopsy proven skin and GI GVHD, liver test function abnormalities were considered indicative of GVHD despite the negative histopathology.
MMF was started at a dose of 1 g twice daily, except in one patient (1.5 mg/day), with a median delay of 6 months between transplant and introduction of MMF (range, 1-45) ( Table 1) . Six patients received MMF before the 100th day following transplantation for treatment of an aGVHD, while MMF was introduced beyond day 100 in 15 patients with extensive cGVHD (median delay of introduction after transplant, 11 months; 3.2-45 months).
Median delay between the onset of aGVHD or cGVHD and MMF introduction was 66 days (range, 1-1194 days) ( Table 1 ). For 18 patients trough plasma concentrations of mycophenolic acid (MPA) and of its inactive glucuronide conjugate (MPAG) were periodically determined using a validated high-performance liquid chromatography (HPLC) method adapted from Tsina et al 26 and Sugioka et al. 27 Response to MMF was defined as an improvement in the clinical and/or biological signs (decrease in distribution of lichenoid or sclerodermous skin changes, return of dermal appendages, decrease in distribution of oral lesions, decrease in digestive symptoms and decrease in bilirubin level) allowing a decrease in dose or discontinuation of MMF and/or in other immunosuppressive treatments. No response inferred progressive worsening of GVHD, leading to the introduction of additional systemic treatment or PUVA or UVB therapy in cases of cGVHD.
Patient outcome
Patient outcomes (clinical course of hematological diseases and of GVHD, overall survival) and clinical and biological parameters relating to the administration of MMF (reason for MMF introduction, date of MMF introduction, dose of MMF administered, treatment associated with MMF, tolerance to MMF, occurrence of infection during MMF administration, response to MMF, plasma concentrations of MPA and MPAG, duration of MMF treatment), were retrospectively reviewed. Student's t-test was used to compare mean MPA trough plasma levels between subgroups. On 1 December 2000, the median duration of MMF administration was 9 months (1-20.5) and median follow-up of patients was 19.5 months (5-71).
Results
MMF as an alternative treatment for aGVHD
Median delay between transplant and introduction of MMF was 6 months (range, 1-45) in 21 patients in these series. Six patients received MMF before day 100 following transplant (median, 1 month; range 1-2.7 months) for treatment of aGVHD grade II-IV: five patients as an alternative treatment because of non-response (three cases) and/or intolerance (five cases) to standard CsA/steroids previously administered. One patient received it as first-line treatment because kidney failure precluded introduction of CsA (patient 3) ( Table 1) . In these patients, aGVHD manifested as involvement of the skin (six cases), and/or liver (three cases) and/or gastrointestinal tract (one case). One patient received MMF alone, while in five patients MMF was given with steroids. Four out of these six patients responded to MMF (including one of the three patients with aGVHD resistant to previous treatment), with no development of subsequent cGVHD. Response was observed in less than 1 week. Among the four responders: one patient died of
Bone Marrow Transplantation infection (Pseudomonas aeruginosa) with GVHD under control 4 months after transplant (patient 4), MMF was stopped in two patients after 3 and 5.5 months respectively (patients 1 and 3), while one patient (No. 2) is still receiving MMF, steroids having been discontinued. In the last two patients who received MMF before the 100th day following transplantation, progression of aGVHD despite MMF required use of an alternative treatment (antilymphocyte serum, 1; CsA, 2; UVB, 1; PUVA, 1; thalidomide, 1; anti-RIL2, 1).
Both patients with refractory aGVHD (patients 5 and 6) died of aspergillosis, with active GVHD, in complete remission of their hematologic malignancies.
Overall, when analyzing the result according to type of aGVHD, improvement was observed in 4/6 skin, 1/3 liver, 0/1 bowel.
MMF an alternative treatment for cGVHD
MMF was introduced after day 100 (median, 11 months; 3.2-45 months) in 15 patients, 13 of whom had clinical and/or biological signs of cGHVD. In one asymptomatic patient, MMF was introduced because it was not possible to continue the immunosuppressive treatment instituted for aGVHD (patient 15 developed TTP while receiving CsA). One patient received MMF for a rise in bilirubin due, in fact, to NHL relapse diagnosed shortly after the introduction of MMF (patient 8). Thus, in terms of opportunistic infections and tolerance to MMF, all 15 patients were evaluable, while only 13 patients with cGVHD (with involvement of skin in 13 cases and/or liver in nine cases and/or GI tract in 3 cases) were evaluable for response to MMF. In four patients MMF was considered first-line treatment for cGVHD and was introduced 1, 2, 4 and 7.5 months after discontinuation of aGVHD treatment or prophylaxis. However, because of the short duration of these immunosuppressive treatment-free intervals, these patients were considered as failures, resistant to previous GVHD treatments. In nine patients, MMF was introduced because of intolerance (four cases) and/or ineffectiveness (seven cases) of previous cGVHD treatment (combinations of steroids (nine cases), PUVA (five cases), CsA (six cases), UVB (one case)). Most patients received steroids together with MMF. In cases of non-response, alternative treatments including PUVA were instituted.
Overall, 69% of patients with cGVHD (9/13) responded to MMF (Table 1) , allowing a decrease and/or discontinuation of other immunosuppressive agents and/or MMF. In all the responding patients a significant improvement in clinical and/or biological cGVHD signs was observed in less than 2 months (median delay, 27 days; range, 8-60 days) and the decrease in the dosage of concurrent immunosuppressive agents was started in seven patients between 3 and 58 days after the introduction of MMF. Reduction in immunosuppression did not result in reactivation, except in patient 10 who finally responded to prolonged administration of MMF. There was no significant difference in terms of incidence of response between skin (nine out of 13 cases with the same response rate for the lichenoid and sclerodermatous subtypes), liver (7/9 cases), and bowel (2/2 cases) cGVHD. In cases of multiple organ involvement no In association or subsequently.
Bone Marrow Transplantation dissociated response was observed in general. Median duration of MMF administration in responding patients was 17.5 months (8.5-20.5ϩ). At the censor point MMF had been stopped along with other immunosuppressive treatments in four patients (8.5, 9, 17.5, 18.5 months after MMF introduction).
Tolerance of MMF
At each visit, patients were evaluated for adverse hematological events, nephrotoxicity or liver toxicity, gastrointestinal disturbances, and opportunistic or severe bacterial infection. Most patients received 2 g MMF per day; a few patients (patients 5, 10, 18, 21) were given 3 g/day because of very low trough plasma levels of mycophenolic acid. None of our patients had an evolving infection at the time of MMF introduction. Overall, MMF was well tolerated, with diarrhea occurring in three patients out of 21 and no other toxicity. However, 22 serious infectious events occurred in 10 patients receiving MMF for treatment of aGVHD (four cases) or cGVHD (six cases). Aspergillosis occurred in two patients with uncontrolled GVHD and resulted in death in both cases (lung involvement, patients 5 and 6; cerebral localisations, patient 6). Six CMV infections were observed. One patient (patient 15) developed encephalitis with clinical features of the Wernicke-Korsakoff syndrome (including impaired memory, nystagmus and ataxia) and MRI (magnetic resonance imaging) showed necrosis of the mamillary bodies, shortly after the onset of a CMV pneumonia. Despite the lack of histology and the fact that no viral DNA was detected by PCR analysis of the cerebrospinal fluid of this patient, CMV was assumed to be the cause of these neurological complications after other potential causes had been eliminated. This assumption was based on a combination of facts (acuteness of the clinical presentation, clinical features, MRI findings and response to ganciclovir). CMV encephalitis is a rare event and similar clinical features with CMV encephalitis have been reported. 28 In patients 4, 6 and 12, detection of CMV viremia led to the administration of antiviral treatment before the onset of CMV disease. Other viral infections were: herpes simplex (three cases); herpes zoster (five cases), BK virus (one case), HHV6 (one case), and papilloma virus in one patient who developed extensive condylomata of the glans. Three serious bacterial infections occurred in patients receiving MMF. One patient died of Pseudomonas aeruginosa septicemia, one was admitted to intensive care with septic shock due a streptococcus B infection, and one patient suffered from recurrent acute epididymitis due to E. coli. Besides these infectious complications, the immunosuppression induced by MMF and associated agents might have been responsible for the occurrence of a skin carcinoma in one patient.
Plasma concentrations of MPA and MPAG
With the exception of one patient who received 1.5 g/day of MMF initially for a few weeks, MMF was started at a dose of 1 g twice daily. This dose corresponded to that used in renal transplant recipients 29 and was arbitrarily considered as appropriate in hematopoietic stem cell recipients, despite the lack of data. Trough plasma levels of mycophenolic acid (MPA) and its inactive glucuronide metabolite (MPAG) were periodically measured by HPLC. In four patients (patients 5, 10, 18, 21) not responding to 2 g/day MMF and demonstrating no side-effects, the MMF dose was increased to 3 g/day. Samples taken while patients received 2 or 3 g/day were available in 18/21 patients in this series (median, six samples/patient; range 1-23).
Mean plasma levels of MPA and MPAG were 1.52 + 1.69 mg/l (range, 0.1-8.94 mg/l) and 42.1 Ϯ 29.6 mg/l (range, 2-178.4 mg/l), respectively. While the MPA level remained relatively stable with time in some patients, repeated analyses showed broad variations in MPA levels in others, and for a given patient a fluctuation factor ranging from 1.5 to 47.2 was thus seen. In addition, mean MPA levels varied between patients from 0.15 mg/l to 4.77 mg/l. Furthermore, the MPAG/MPA ratio varied from 0.5 to 264 depending on time points and patients. However, despite these variations, there was a trend towards a higher mean MPA plasma level in the subgroup of patients who responded to MMF (2.48 Ϯ 2.56 mg/l; range, 0.14-12.75) than in the subgroup of non-responsive patients (1.58 Ϯ 1.40 mg/l; range, 0.10-5.35) with a difference of borderline statistical significance (P ϭ 0.058). No correlation between plasma MMF levels and the presence of bowel cGVHD could be demonstrated: mean plasma MPA levels in patients with bowel involvement were 1.52 Ϯ 1.69 mg/l (range, 0.10-8.94) while patients without gastrointestinal tract GVHD had a mean plasma MPA level of 2.42 Ϯ 2.35 mg/l (range, 0.13-12.75) (P ϭ 0.579). We finally compared mean plasma MPA levels between patients who developed opportunistic or severe viral or bacterial infections and patients who did not experience any major infectious complications: no significant difference was observed between the two groups of patients (mean MPA levels: 2.10 Ϯ 2.38 mg/l and 1.54 Ϯ 1.32 mg/l, respectively; P ϭ 0.84).
Patient outcome
Five patients in this series died within the study period due to relapse of their hematological malignancy in two cases, or to sepsis in three cases (two aspergillosis, one Pseudomonas aeruginosa) in the context of uncontrolled GVHD for two. At the time of this report 16 patients are alive in complete remission from their hematological malignancy, 10 of them still receiving MMF (six responding and four refractory to MMF), while MMF had been discontinued in six of them, because of lack of efficacy (five patients) or occurrence of severe infection (one patient).
Discussion
Effective prophylaxes and treatments for GVHD, a significant cause of morbidity and mortality after allogeneic stem cell transplantation, are needed. The optimal treatment of cGVHD, a major determinant of long-term outcome and quality of life following BMT, is still controversial. There is no evidence that any particular immunosuppressive treat-ment regimen is superior to another in terms of prolonging survival in cGVHD patients.
The combination of cyclosporine and prednisone is currently considered as the standard first line treatment for extensive cGVHD based on studies by Sullivan et al conducted in the late 1980s 12, 30 and discussed in the recent review by Vogelsang. 15 Patients who fail on standard therapy have a bad prognosis: therapeutic options are limited and salvage therapies have produced disappointing results to date. The use of MMF alone or in combination with other immunosuppressive agents for prophylaxis of aGVHD and/or for treatment of acute or chronic GVHD is increasing. However, few data concerning the efficacy and safety (especially in terms of infectious risks) are available. We ran a retrospective study on 21 allogeneic SC transplant patients who received MMF because of intolerance (52%) and/or failure (67%) to respond to aGVHD (six patients) or cGVHD (15 patients) CsA-containing treatments, in order to assess whether the use of MMF might be beneficial.
Response to MMF (given with steroids in 81% of the cases) was observed in 68% of the patients, while 32% experienced progressive worsening of GVHD leading to the introduction of additional treatments. Four of the six aGVHD patients responded, with no development of subsequent cGVHD, the MMF being stopped because of a successful outcome in two of these patients.
Sixty-nine percent of cGVHD cases responded to MMF with a median delay between the introduction of MMF and improvement in clinical and/or biological signs of cGVHD of 27 days (range, 8-60 days), a median duration of MMF administration of 17.5 months (8.5-20.5ϩ) and discontinuation of MMF in four patients. These results were in the range of the ones reported in previous studies on aGVHD (71% overall GVHD grade improvement in the series by Basara et al . However, lack of comparative studies and differences in patient characteristics between studies do not allow a conclusion concerning the real benefit of MMF compared to other immunosuppressive agents. Interestingly, for aGVH as well as for cGVHD we found no significant difference in terms of incidence of response between skin, liver and bowel involvement, and in cases of multiple organ involvement, no disassociated responses were observed. Response rates were the same for lichenoid and sclerodermatous skin cGVHD subtypes. In the study by Mookerjee et al 14 no correlation was found between number of organs involved and response as about half the patients with either skin only or multiple organ involvement experienced improvement with the combination of MMF and tacrolimus. In the study by Busca et al, 24 the best responses were seen in children with cGVHD of the gastrointestinal tract (60% complete responses) or of the mouth (33% complete responses) or with skin involvement that did not include sclerodermatous manifestations (43% complete response).
Diarrhea, the most frequently reported side-effect of MMF treatment, occured in three of our patients, while no significant hematological events were observed, compared
Bone Marrow Transplantation to 20% leukopenia, 13% anemia and 17% thrombocytopenia which occurred in the study by Basara et al. 22 Overall, MMF was well tolerated; however 22 opportunistic or severe viral or bacterial infections occurred in 10 patients. Three patients in our series (14.2%) died from infection (two invasive aspergillosis, one Pseudomonas aeruginosa septicemia), which developed while receiving MMF and one patient developed CMV pneumonia and encephalitis which was assumed to be due to CMV. In this series, 12 patients were transplanted with early disease and nine with advanced disease. Because of the small number of patients, influence on infection risk of the pre-allograft treatment, status of the malignancy at time of allograft, influence of serological viral status (especially for CMV) at time of transplant, or of treatments associated with MMF could not be evaluated, and it is difficult to ascertain the significance of MMF on infectious complications. The infections which occurred in these patients were not unexpected. The lack of a comparison group precludes any firm conclusions about a higher incidence of infectious complications in patients receiving MMF in comparison to other GVH salvage treatments. However, MMF administration might have increased the infection risk in patients already immunocompromised. Several studies on renal transplant recipients indicate that the increased immunosuppressive activity of MMF impacts upon the morbidity of CMV infection. Ter Meulen et al 31 found that the addition of MMF to the CsAprednisone combination did not result in an increase in primary CMV infections, but CMV infections led more often to CMV disease in patients treated with MMF than was the case in those not receiving MMF. In the study by Sarmiento et al, 32 MMF did not increase the overall incidence of CMV infection in renal transplant patients, but increased the severity of CMV infection in terms of the frequency of organ involvement and number of organs involved.
Analysis of trough plasma levels of the active metabolite of MMF (MPA) available in 18 patients showed broad fluctuations over time for some patients and important variations in mean levels between patients. We found a trend towards a higher mean MPA concentration in patients responding to MMF. No correlation between mean MPA concentration and occurrence of side-effects or infectious complications was found, or between MPA level and bowel involvement. In the study by Kiehl et al 33 a median steadystate pre-dose plasma MPA concentration of 0.47 mg/l was observed in 14 patients with aGVHD and in comparison to patients with skin aGVHD, patients with gut aGVHD had lower MPA concentrations. In addition, MPA concentration was significantly greater in responders than in nonresponders, and the incidence of response was higher in patients without gut involvement. The same authors have evaluated the use of i.v. formulation of MMF for GVHD prophylaxis: MPA plasma levels were high immediately after MMF infusion, but decreased rapidly within the next 2 h, and no differences in MPA plasma levels were observed when comparing patients with or without GVHD and there was no correlation with the occurrence of sideeffects. For the same dose of MMF, MPA trough levels varied from one study to the other, and one should notice that the mean MPA plasma level we found in our patients was 1.52 Ϯ 1.69 mg/l (range, 0.1-8.94 mg/l). In the study by Bornhaüser et al, 20 trough blood levels of MPA and MPAG in BMT patients who received 2 g of oral MMF were 1.28 mg/l and 5.7 mg/l, respectively. In the study by Weber et al 29 on adult renal transplant recipients receiving 2 g MMF orally in combination with CsA and prednisolone, a median pre-dose MPA concentration of 0.73 mg/l was observed 1 week after transplantation.
The pharmacokinetics of some immunosuppressive agents, such as cyclosporine, tacrolimus, MMF are complex and unpredictable. 34 A narrow therapeutic index unique to each patient, as well as variable absorption, distribution and elimination, are characteristics of these drugs. It might be that the determination of MPA trough plasma levels is not the most relevant parameter for predicting MMF efficacy or toxicity. In renal transplant recipients, correlations between pharmacokinetic parameters and clinical effectiveness (diminution of acute rejection) have been demonstrated when measuring the MPA 'area under the concentration-time curve' (AUC) and a pharmacokineticpharmacodynamic correlation between MPA and the occurrence of side-effects has been suggested. 35, 36 This study shows that MMF can be efficiently and safely used for the treatment of GVHD. Most patients in our series experienced significant improvement in clinical and/or biological signs of GVHD. Treatment with MMF was not discontinued in any of our patients because of adverse events. However, the incidence of severe infectious complications was high. A prospective, randomized clinical trial is needed to assess the impact of MMF in the treatment of GVHD. Broad and prolonged antimicrobial prophylaxis combining antiviral, antibacterial, antifungal agents with Pneumocytis carinii prophylaxis might be needed during MMF administration and even in the months following MMF discontinuation. In addition, repeated doses allowing measurement of the AUC and determination of peak levels might be more appropriate than determination of MPA trough levels in predicting MMF efficacy and side-effects.
